367 related articles for article (PubMed ID: 17284383)
21. Is seminal vesicle implantation with permanent sources possible? A dose-volume histogram analysis in patients undergoing combined 103Pd implantation and external beam radiation for T3c prostate cancer.
Ho AY; Burri RJ; Jennings GT; Stone NN; Cesaretti JA; Stock RG
Brachytherapy; 2007; 6(1):38-43. PubMed ID: 17284384
[TBL] [Abstract][Full Text] [Related]
22. Dose escalation in permanent brachytherapy for prostate cancer: dosimetric and biological considerations.
Li XA; Wang JZ; Stewart RD; DiBiase SJ
Phys Med Biol; 2003 Sep; 48(17):2753-65. PubMed ID: 14516099
[TBL] [Abstract][Full Text] [Related]
23. 192Ir or 125I prostate brachytherapy as a boost to external beam radiotherapy in locally advanced prostatic cancer: a dosimetric point of view.
Nickers P; Thissen B; Jansen N; Deneufbourg JM
Radiother Oncol; 2006 Jan; 78(1):47-52. PubMed ID: 16216365
[TBL] [Abstract][Full Text] [Related]
24. Some treatment planning considerations for 103Pd and 125I permanent interstitial implants.
Nath R; Meigooni AS; Melillo A
Int J Radiat Oncol Biol Phys; 1992; 22(5):1131-8. PubMed ID: 1555965
[TBL] [Abstract][Full Text] [Related]
25. Prostate implant nomograms for the North American Scientific 103Pd seed.
Zheng JJ; Stevens RN
Med Dosim; 2003; 28(3):185-8. PubMed ID: 14563438
[TBL] [Abstract][Full Text] [Related]
26. Potential role of various dosimetric quality indicators in prostate brachytherapy.
Merrick GS; Butler WM; Dorsey AT; Lief JH
Int J Radiat Oncol Biol Phys; 1999 Jun; 44(3):717-24. PubMed ID: 10348304
[TBL] [Abstract][Full Text] [Related]
27. Isotope choice and the effect of edema on prostate brachytherapy dosimetry.
Butler WM; Merrick GS; Dorsey AT; Lief JH
Med Phys; 2000 May; 27(5):1067-75. PubMed ID: 10841411
[TBL] [Abstract][Full Text] [Related]
28. Recommendations of the American Association of Physicists in Medicine on 103Pd interstitial source calibration and dosimetry: implications for dose specification and prescription.
Williamson JF; Coursey BM; DeWerd LA; Hanson WF; Nath R; Rivard MJ; Ibbott G
Med Phys; 2000 Apr; 27(4):634-42. PubMed ID: 10798683
[TBL] [Abstract][Full Text] [Related]
29. A dynamic model for the estimation of optimum timing of computed tomography scan for dose evaluation of 125I or 103Pd seed implant of prostate.
Yue N; Dicker AP; Corn BW; Nath R; Waterman FM
Int J Radiat Oncol Biol Phys; 1999 Jan; 43(2):447-54. PubMed ID: 10030274
[TBL] [Abstract][Full Text] [Related]
30. Monte Carlo dosimetry for 125I and 103Pd eye plaque brachytherapy with various seed models.
Thomson RM; Rogers DW
Med Phys; 2010 Jan; 37(1):368-76. PubMed ID: 20175499
[TBL] [Abstract][Full Text] [Related]
31. American brachytherapy society recommendations for clinical implementation of NIST-1999 standards for (103)palladium brachytherapy. The clinical research committee of the American Brachytherapy Society.
Beyer D; Nath R; Butler W; Merrick G; Blasko J; Nag S; Orton C
Int J Radiat Oncol Biol Phys; 2000 May; 47(2):273-5. PubMed ID: 10802349
[TBL] [Abstract][Full Text] [Related]
32. Interstitial brachytherapy dosimetry update.
Rivard MJ; Nath R
Radiat Prot Dosimetry; 2006; 120(1-4):64-9. PubMed ID: 16614084
[TBL] [Abstract][Full Text] [Related]
33. Rectal dosimetric analysis following prostate brachytherapy.
Merrick GS; Butler WM; Dorsey AT; Lief JH; Walbert HL; Blatt HJ
Int J Radiat Oncol Biol Phys; 1999 Mar; 43(5):1021-7. PubMed ID: 10192350
[TBL] [Abstract][Full Text] [Related]
34. Calculated microdosimetric characteristics of 125I and 103Pd brachytherapy seeds at different depths in water.
Wuu CS; Chen J
Radiat Prot Dosimetry; 2006; 122(1-4):506-8. PubMed ID: 17189276
[TBL] [Abstract][Full Text] [Related]
35. Extracapsular radiation dose distribution after permanent prostate brachytherapy.
Merrick GS; Butler WM; Wallner KE; Burden LR; Dougherty JE
Am J Clin Oncol; 2003 Oct; 26(5):e178-89. PubMed ID: 14528094
[TBL] [Abstract][Full Text] [Related]
36. [Physical brachytherapy planning].
Muskalla K
Praxis (Bern 1994); 2001 Sep; 90(36):1532-43. PubMed ID: 11593909
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of radiobiologic biochemical control in a large permanent prostate brachytherapy population from a single institution using AAPM TG-137 parameters.
Butler WM; Stewart RR; Merrick GS
Brachytherapy; 2011; 10(1):16-28. PubMed ID: 20149981
[TBL] [Abstract][Full Text] [Related]
38. Prostatic acid phosphatase adversely affects cause-specific survival in patients with intermediate to high-risk prostate cancer treated with brachytherapy.
Fang LC; Dattoli M; Taira A; True L; Sorace R; Wallner K
Urology; 2008 Jan; 71(1):146-50. PubMed ID: 18242384
[TBL] [Abstract][Full Text] [Related]
39. The impact of edema on planning 125I and 103Pd prostate implants.
Yue N; Dicker AP; Nath R; Waterman FM
Med Phys; 1999 May; 26(5):763-7. PubMed ID: 10360539
[TBL] [Abstract][Full Text] [Related]
40. A detailed radiobiological and dosimetric analysis of biochemical outcomes in a case-control study of permanent prostate brachytherapy patients.
Butler WM; Stewart RR; Merrick GS
Med Phys; 2009 Mar; 36(3):776-87. PubMed ID: 19378738
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
